View Clinical Trial (Medical Research Study)
A Long-Term Follow-up Study of Subjects Who Participated in a Clinical Trial in Which Asunaprevir (BMS-650032) and/or Daclatasvir (BMS-790052) Was Administered for the Treatment of Chronic Hepatitis C
| City: |
|
Tulsa |
| State: |
|
Oklahoma |
| Zip Code: |
|
74104 |
| Conditions: |
|
Hepatitis C |
| Purpose: |
|
The primary purpose of this study is to determine whether the hepatitis C virus continues to
remain unable to be detected in subjects who were previously treated with Asunaprevir
(BMS-650032) and/or Daclatasvir (BMS-790052) and achieved sustained virologic response.
|
| Study Summary: |
|
|
| Criteria: |
|
Inclusion Criteria:
- Received at least one dose of Asunaprevir (BMS-650032) and/or Daclatasvir
(BMS-790052) and completed participation in a previous study
1. Subjects participating in Daclatasvir (BMS-790052) and/or Asunaprevir
(BMS-650032) studies may enroll regardless of virologic response (subjects who
received control agents, eg, placebo, will be allowed to participate until
unblinded treatment information is released for the parent protocol; at that
time subjects will have the option to continue in the study)
2. Subjects participating in BMS-914143 (pegylated interferon lambda 1a) studies
must have Hepatitis C virus (HCV) Ribonucleic acid (RNA) ≥ Limit of Quantitation
(LOQ) at the completion of the post-treatment follow-up period
- Enrolled within 6 months of completing previous study or within 6 months of protocol
availability
Exclusion Criteria:
- Treatment with any antiviral or immunomodulatory drug for hepatitis C after
completion of the previous study
|
| NCT ID: |
|
NCT01492504 |
| Primary Contact: |
|
Study Director
Bristol-Myers Squibb
Bristol-Myers Squibb
For participation information at a USA site use a phone number below. For site information outside the USA please email:
Email: Clinical.Trials@bms.com
|
| Backup Contact: |
|
First line of email MUST contain NCT# & Site#. Only trial sites that are recruiting have contact information at this time.
|
| Location Contact: |
|
Tulsa, Oklahoma 74104
United States
Harvey A Tatum, Site 025
Phone: 918-513-3490
Site Status: Recruiting |
| Data Source: |
|
ClinicalTrials.gov |
| Date Processed: |
|
May 22, 2013 |
| Modifications to this listing: |
|
Only selected fields are shown, please use the link
below to view all information about this clinical trial. |
|
Click to view Full Listing
|